MENU

LXEO Stock Lexeo Therapeutics (LXEO, $3.88) was a top quarterly gainer, rising +43.7%

A.I.dvisor
at Tickeron.com
Loading...
LXEO - Lexeo Therapeutics
Tickeron

Loading...

Price: $3.88
Daily change: +$0.61 (+18.65%)
Daily volume: 1.9M
3-month price change: +$1.18 (+43.7%)
Capitalization: $128.8M
Industry: Biotechnology
Lexeo Therapeutics (LXEO, $3.88) was one of top quarterly gainers, jumping to $3.88 per share. A.I.dvisor analyzed 831 stocks in the Biotechnology Industry over the last three months, and discovered that of them (5) charted an Uptrend while of them (4) trended down.

LXEO's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for LXEO turned positive on July 31, 2025. Looking at past instances where LXEO's MACD turned positive, the stock continued to rise in of 15 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 30, 2025. You may want to consider a long position or call options on LXEO as a result. In of 28 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

LXEO moved above its 50-day moving average on July 25, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LXEO advanced for three days, in of 112 cases, the price rose further within the following month. The odds of a continued upward trend are .

LXEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 33 cases where LXEO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXEO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LXEO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.720) is normal, around the industry mean (18.130). P/E Ratio (0.000) is within average values for comparable stocks, (57.859). LXEO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.470). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (276.117).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
LXEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. LXEO showed earnings on May 13, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
345 Park Avenue South
Phone
+1 212 547-9879
Employees
58
Web
https://www.lexeotx.com